大理药业(603963) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥15,320,299.73, representing a decrease of 58.47% compared to the same period last year[6] - The net profit attributable to shareholders was a loss of ¥5,375,021.63, with a basic and diluted earnings per share of -¥0.0245[6] - Total operating revenue for Q1 2024 was CNY 15,320,299.73, a decrease of 58.5% compared to CNY 36,887,280.13 in Q1 2023[18] - Net loss for Q1 2024 was CNY 5,375,021.63, compared to a net loss of CNY 2,551,643.71 in Q1 2023, indicating a worsening of 110.5%[19] - The total comprehensive income attributable to the parent company was -5,375,021.63 RMB, compared to -2,551,643.71 RMB in Q1 2023, indicating a larger loss[20] - Basic and diluted earnings per share were both -0.0245 RMB, worsening from -0.0116 RMB in the previous year[20] Assets and Equity - Total assets at the end of Q1 2024 were ¥461,336,787.73, down 2.64% from the end of the previous year[7] - The equity attributable to shareholders decreased by 1.41% to ¥375,749,963.33 compared to the end of the previous year[7] - Total assets decreased to CNY 461,336,787.73 in Q1 2024 from CNY 473,833,811.62 in Q1 2023, a decline of 2.6%[16] - Total equity attributable to shareholders decreased to CNY 375,749,963.33 in Q1 2024 from CNY 381,124,984.96 in Q1 2023, a decline of 1.1%[16] Cash Flow - Cash flow from operating activities was a negative ¥5,279,293.86, indicating a significant cash outflow[6] - In Q1 2024, the company reported a net cash flow from operating activities of -5,279,293.86 RMB, compared to -5,206,773.92 RMB in Q1 2023, indicating a slight deterioration in operational cash flow[22] - Total cash inflow from operating activities was 13,398,683.12 RMB, down 67.2% from 40,925,167.74 RMB in the same period last year[22] - The company experienced a significant decrease in cash received from sales, totaling 10,925,652.54 RMB, a decline of 71.8% from 38,767,624.85 RMB in Q1 2023[22] - Cash outflow for purchasing goods and services was 7,163,037.05 RMB, down 36.5% from 11,326,431.60 RMB in the previous year[23] - The net cash flow from investing activities was 31,018,747.78 RMB, an increase of 55.8% compared to 19,950,157.84 RMB in Q1 2023[23] - The company reported a net increase in cash and cash equivalents of 25,486,759.20 RMB, compared to 11,756,096.11 RMB in the same quarter last year, reflecting improved liquidity[24] - The ending balance of cash and cash equivalents was 39,680,747.92 RMB, down from 55,595,123.10 RMB in Q1 2023[24] Costs and Expenses - Total operating costs for Q1 2024 were CNY 21,992,916.15, down 45.5% from CNY 40,512,116.52 in Q1 2023[18] - Research and development expenses increased to CNY 699,464.63 in Q1 2024, up 359.5% from CNY 151,998.65 in Q1 2023[18] - The company reported a significant increase in sales expenses to CNY 3,216,092.49 in Q1 2024, compared to CNY 18,779,591.02 in Q1 2023, reflecting a strategic shift in marketing efforts[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,691[10]